Molecularly distinct models of zebrafish Myc-induced B cell leukemia
Preprint posted on November 06, 2018 https://www.biorxiv.org/content/early/2018/11/06/446245
Article now published in Leukemia at http://dx.doi.org/10.1038/s41375-018-0328-1
Acute lymphoblastic leukemia (ALL) arises from lymphoblasts within the bone marrow. Lymphoblasts differentiate into either immature T or B cells, which are the cells-of-origin for the two main subclasses of ALL, T-ALL and B-ALL. Zebrafish models of T-ALL have been used successfully for the past 15 years, as their haematological, immunological and oncological pathways are highly conserved in humans. However, despite the clinical relevance of pre (precursor)-B-ALL, as it is the most common paediatric cancer, zebrafish B-ALL models went unrecognised until very recently.
Earlier this year, the Langenau and Frazer labs both published independent reports in the journal Leukemia detailing their discovery of zebrafish B-ALL models within pre-existing T-ALL models ,. Both groups used zebrafish expressing an oncogenic Myc transgene driven by the B/T cell-specific recombination gene rag2 promoter, which caused fish to develop ALLs. It was assumed from previous research that only T-ALL leukemias would develop in these models, but unexpectedly, both groups found a subpopulation of leukemias that were phenotypically and transcriptionally characteristic of B-ALL, or in one case, a mixture of B- and T-ALL (termed biphenotypic ALL). Where the two models differ is the species origin of the Myc transgene, and the genetic background of the fish – the Langenau group use a murine-derived Myc transgene (mMyc) and the Frazer group use a human-derived transgene (hMYC). Although these transgenes are highly similar, it raises the possibility that the leukemias generated by the two models might have important differences that could both undermine or expand their usefulness in modelling human ALL.
In this preprint, the two groups show the results of their collaboration to validate, compare and contrast these B-ALL models at the transcriptional level. Happily, they confirm both models as driving B-ALL formation alongside T-ALL, and also find that unexpectedly, their B-ALLs originate from different B cell lineages, thus potentially modelling different subtypes of B-ALL.
First of all, the authors performed RNA-seq on 13 hMYC ALLs so that they could be compared to the published mMyc RNA-seq data. Principal component analyses of expression profiles from both datasets showed that the data clustered not according to species’ transgene, but whether they were more characteristic of T-ALL or B-ALLs, with the single biphenotypic ALL clustering between the two groups, as shown in Figure 1A from the preprint, below:
From Figure 1A of the preprint (under CC-BY-NC-ND 4.0).
This is a PCA plot of RNAseq expression profiles from previously classified mMyc-induced ALL (blue, red and pink), and hMYC-induced ALL (black). The previously proposed hMYC T-ALLs (2, 6, 8-11, 13,14) cluster near mMyc T-ALLs (blue), proposed hMYC B-ALLs (3-5) near mMyc B-ALLs (red) and two hMYC ALLs (1 & 12) near the mMyc biphenotypic-ALL (pink).
The identities of tumours within these clusters was confirmed by hierarchical clustering with the top 100 positively/negatively regulated genes, which showed that all T-ALLs expressed the same T cell markers, B-ALLs expressed B cell markers and biphenotypic/mixed ALLs expressed a mixture of these.
Differences between the two models were revealed upon investigating the clonality and maturation of B and T cell receptors in hMYC and mMyc ALLs. Perhaps unsurprisingly, the T cell receptor tcrβ was expressed in all T- and biphenotypic-ALLs, but absent in B-ALLs. Interestingly, B-ALL leukemias differed in which B-cell receptor they preferred to express, with hMYC B-ALLs favouring the ighz form and mMyc-driven B-ALLs favouring the ighm form. Ontological comparison of genes uniquely expressed in T-ALLs, hMYC ighz+ B-ALLs and mMyc ighm+ B-ALLs, confirmed a transcriptional divergence between the two B-ALL types.
Taken together, this suggests that although the oncogene driving B-ALL in both models is very similar, they appear to be derived from different B cell lineages. This is exciting, as it means that we have gone from being able to model just T-ALL in zebrafish, to being able to model three more subtypes of ALL – hMYC ighz+ B-ALL, mMyc ighm+ B-ALL, as well as biphenotypic ALL.
Why I chose this preprint
The ‘Confirmatory Results’ is a new tag for me on Biorxiv.org, as most of the uploaded reports I’ve found so far fall into the ‘New Results’ category. With the rise in media coverage about the lack of reproducibility in scientific studies, it is good to see groups collaborating to confirm and build upon their research, and to make these findings accessible to everyone. From a disease modelling standpoint, detailed characterisation and comparison of new models is important so we know how closely they recapitulate different facets of human pathologies. It will be exciting to see how these B-ALL models can now be employed to explore any differences in their molecular aetiologies and treatment responses alongside their T-ALL counterparts.
- It is intriguing that hMYC and mMyc transgenes give rise to transcriptionally divergent B-ALLs – are there any differences in tumour latency, aggressiveness and phenotype in general that could arise from these transcriptional differences?
- Do the different transcriptional profiles of ighm+ and ighz+ B-ALLs correlate with those arising from particular B cell lineages in patients?
- What are the key questions you want to address first with your B-ALL models?
The articles this preprint compares:
Borga, C. et al., 2018. Simultaneous B and T cell acute lymphoblastic leukemias in zebrafish driven by transgenic MYC: implications for oncogenesis and lymphopoiesis. Leukemia.
Garcia, E.G. et al., 2018. Cell of origin dictates aggression and stem cell number in acute lymphoblastic leukemia. Leukemia, 32(8), pp.1860–1865.
Posted on: 3rd December 2018Read preprint
Also in the cancer biology category:
Hyperactive end joining repair mediates resistance to DNA damaging therapy in p53-deficient cells
|Selected by||Matthew Burke|
Spatial heterogeneity of cell-matrix adhesive forces predicts human glioblastoma migration
|Selected by||Mariana De Niz|
Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments
|Selected by||Ankita Jha|
preListscancer biology category:in the
ASCB EMBO Annual Meeting 2019
A collection of preprints presented at the 2019 ASCB EMBO Meeting in Washington, DC (December 7-11)
|List by||Madhuja Samaddar, Ramona Jühlen, Amanda Haage, Laura McCormick, Maiko Kitaoka|
Lung Disease and Regeneration
This preprint list compiles highlights from the field of lung biology.
|List by||Rob Hynds|
Anticancer agents: Discovery and clinical use
Preprints that describe the discovery of anticancer agents and their clinical use. Includes both small molecules and macromolecules like biologics.
|List by||Zhang-He Goh|
Biophysical Society Annual Meeting 2019
Few of the preprints that were discussed in the recent BPS annual meeting at Baltimore, USA
|List by||Joseph Jose Thottacherry|